Oxidized low-density lipoproteins and their antibodies: Relationships with the reverse cholesterol transport and carotid atherosclerosis in adults without cardiovascular diseases


Autoria(s): Ferreira, Paolla F. C.; Zago, Vanessa H. S.; D'Alexandri, Fabio L.; Panzoldo, Natalia B.; Gidlund, Magnus Ake; Nakamura, Rui T.; Schreiber, Roberto; Parra, Eliane S.; Santiago, Fernanda D.; Nakandakare, Edna Regina; Quintao, Eder Carlos Rocha; de Faria, Eliana C.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

04/11/2013

04/11/2013

2012

Resumo

Background: Metabolic predictors and the atherogenicity of oxidized LDL (oxLDL) and the specific antibodies against oxLDL (oxLDL Ab) are unclear and controversial. Methods: In 107 adults without atherosclerotic manifestations, we measured oxLDL and oxLDL Ab, and also the activities of CETP. PLTP, lipases and the carotid intima-media thickness (cIMT). Comparisons were performed for the studied parameters between the lowest and the highest tertile of oxLDL and oxLDL Ab, and the relationships between studied variables were evaluated. Results: Subjects with higher oxLDL Ab present reduced hepatic lipase activity and borderline increased cIMT. In the highest oxLDL tertile, besides the higher levels of total cholesterol, LDL-C and apoB100, we found reduced CETP activity and higher cIMT. A significant correlation between oxLDL Ab and cIMT, independent of oxLDL, and a borderline correlation between oxLDL and cIMT independent of oxLDL Ab were found. In the multivariate analysis, apoAl was a significant predictor of oxLDL Ab, in contrast to regulation of oxLDL by apoB100, PLTP and inverse of CETP. Conclusions: In adults without atherosclerotic disease, the metabolic regulation and carotid atherosclerosis of oxLDLAb and oxLDL groups, characterized a dual trait in oxLDL Ab, as a contributor to carotid atherosclerosis, much less so than oxidized LDL, and with a modest atheroprotective role. (C) 2012 Elsevier B.V. All rights reserved.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, SP, Brazil [FAPESP: 2006/60585-9]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, SP, Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil [471380/2008-3]

Identificador

CLINICA CHIMICA ACTA, AMSTERDAM, v. 413, n. 19-20, supl., Part 3, pp. 1472-1478, OCT 9, 2012

0009-8981

http://www.producao.usp.br/handle/BDPI/37991

10.1016/j.cca.2012.05.020

http://dx.doi.org/10.1016/j.cca.2012.05.020

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

AMSTERDAM

Relação

CLINICA CHIMICA ACTA

Direitos

closedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #OXIDIZED LDL #ANTIBODIES AGAINST OXIDIZED LDL #CAROTID INTIMA-MEDIA THICKNESS #CHOLESTERYL ESTER TRANSFER PROTEIN #PHOSPHOLIPID TRANSFER PROTEIN #HEPATIC LIPASE #INTIMA-MEDIA THICKNESS #ESTER TRANSFER PROTEIN #CORONARY HEART-DISEASE #APOLIPOPROTEIN-A-I #IMMUNE-COMPLEXES #HEALTHY POPULATION #HDL-CHOLESTEROL #LDL #OXLDL #RISK #MEDICAL LABORATORY TECHNOLOGY
Tipo

article

original article

publishedVersion